Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

doi:10.1016/j.ejca.2017.11.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

European journal of cancer (Oxford, England : 1990) - 1 Jan 2018

von Moos Roger, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Rauch Daniel, Saletti Piercarlo, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin

Abstract excerpt

BACKGROUND: KRAS mutation occurs in ∼40% of locally advanced rectal cancers (LARCs). The multitarget tyrosine kinase inhibitor sorafenib has radiosensitising effects and might improve outcomes for standard preoperative chemoradiotherapy in patients with KRAS-mutated LARC. METHODS: Adult patients with KRAS-mutated T3/4 and/or N1/2M0 LARC were included in this phase I/II study. The phase I dose-escalation study of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Chemoradiotherapy

Share to Niacinamide

Share to Phenylurea Compounds

Share to Radiotherapy, Adjuvant

Share to Rectal Neoplasms

Share to Sorafenib

Source

Open in PubMed

Identifiers

PMID: 29241084
DOI: 10.1016/j.ejca.2017.11.005

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).PMID 29241084Read ↗

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).Semantic proximity Read ↗

KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.Semantic proximity Read ↗

Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.Semantic proximity Read ↗

KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Semantic proximity Read ↗

Influence of KRAS mutation subtypes on response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: meta-analysis.Semantic proximity Read ↗

Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.Semantic proximity Read ↗

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.Semantic proximity Read ↗

Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.Semantic proximity Read ↗

Total Neoadjuvant Therapy and Organ Preservation in Locally Advanced Rectal Cancer: A State-of-the-Art Systematic Review and Critical AppraisalSemantic proximity Read ↗

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.Semantic proximity Read ↗

Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.Semantic proximity Read ↗

Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.